Concepts (133)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Caregivers | 6 | 2023 | 2224 | 1.060 |
Why?
|
| Glioma | 5 | 2023 | 3420 | 1.010 |
Why?
|
| Brain Neoplasms | 9 | 2023 | 8986 | 0.890 |
Why?
|
| Neurotoxicity Syndromes | 3 | 2023 | 299 | 0.770 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2022 | 1403 | 0.710 |
Why?
|
| Skull Base Neoplasms | 1 | 2023 | 269 | 0.700 |
Why?
|
| Meningeal Neoplasms | 3 | 2023 | 1249 | 0.680 |
Why?
|
| Stuttering | 1 | 2018 | 25 | 0.640 |
Why?
|
| Neuroendocrine Tumors | 1 | 2023 | 650 | 0.570 |
Why?
|
| Palliative Care | 2 | 2023 | 3607 | 0.560 |
Why?
|
| Antigens, CD19 | 2 | 2022 | 424 | 0.550 |
Why?
|
| Central Nervous System Neoplasms | 5 | 2024 | 916 | 0.540 |
Why?
|
| Immunotherapy, Adoptive | 4 | 2023 | 1454 | 0.530 |
Why?
|
| Frontal Lobe | 1 | 2022 | 1420 | 0.500 |
Why?
|
| Pituitary Neoplasms | 1 | 2023 | 1313 | 0.490 |
Why?
|
| Accidental Falls | 1 | 2022 | 1056 | 0.460 |
Why?
|
| Managed Care Programs | 1 | 2018 | 939 | 0.410 |
Why?
|
| Lymphoma | 4 | 2024 | 1898 | 0.410 |
Why?
|
| Hospice Care | 1 | 2018 | 692 | 0.370 |
Why?
|
| Meningeal Carcinomatosis | 2 | 2021 | 63 | 0.360 |
Why?
|
| Brain Diseases | 1 | 2018 | 1540 | 0.340 |
Why?
|
| Length of Stay | 1 | 2018 | 6479 | 0.230 |
Why?
|
| T-Lymphocytes | 2 | 2023 | 10181 | 0.200 |
Why?
|
| Glioblastoma | 3 | 2021 | 3484 | 0.200 |
Why?
|
| Granuloma, Foreign-Body | 1 | 2021 | 42 | 0.190 |
Why?
|
| Skull Base | 1 | 2023 | 291 | 0.180 |
Why?
|
| Inositol | 1 | 2021 | 215 | 0.180 |
Why?
|
| Anemia, Aplastic | 1 | 2022 | 228 | 0.180 |
Why?
|
| Anxiety | 4 | 2022 | 4538 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2021 | 346 | 0.150 |
Why?
|
| Mosaicism | 1 | 2021 | 466 | 0.150 |
Why?
|
| Cerebellar Neoplasms | 1 | 2022 | 587 | 0.150 |
Why?
|
| Medulloblastoma | 1 | 2022 | 679 | 0.140 |
Why?
|
| Humans | 31 | 2024 | 760621 | 0.130 |
Why?
|
| Patients | 1 | 2022 | 906 | 0.130 |
Why?
|
| Depression | 4 | 2022 | 8044 | 0.120 |
Why?
|
| Goals | 1 | 2020 | 708 | 0.120 |
Why?
|
| Neurology | 1 | 2021 | 779 | 0.110 |
Why?
|
| Quality of Life | 3 | 2023 | 13308 | 0.110 |
Why?
|
| Meningioma | 1 | 2022 | 1221 | 0.110 |
Why?
|
| Fellowships and Scholarships | 1 | 2021 | 1116 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 2536 | 0.110 |
Why?
|
| SEER Program | 1 | 2018 | 1530 | 0.100 |
Why?
|
| Neurosurgical Procedures | 1 | 2023 | 2056 | 0.100 |
Why?
|
| Activities of Daily Living | 1 | 2022 | 2417 | 0.100 |
Why?
|
| Prognosis | 5 | 2022 | 29658 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2021 | 2049 | 0.100 |
Why?
|
| Influenza A virus | 1 | 2015 | 457 | 0.100 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2021 | 3765 | 0.090 |
Why?
|
| Adaptation, Psychological | 1 | 2022 | 2628 | 0.090 |
Why?
|
| Encephalitis | 1 | 2015 | 437 | 0.090 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2015 | 640 | 0.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2021 | 2053 | 0.090 |
Why?
|
| Terminal Care | 1 | 2023 | 1758 | 0.090 |
Why?
|
| Biopsy | 1 | 2022 | 6771 | 0.090 |
Why?
|
| Medical Oncology | 1 | 2021 | 2313 | 0.090 |
Why?
|
| Biological Products | 1 | 2018 | 916 | 0.080 |
Why?
|
| Methotrexate | 1 | 2015 | 1719 | 0.080 |
Why?
|
| Nausea | 2 | 2021 | 678 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2022 | 12965 | 0.070 |
Why?
|
| Stress, Psychological | 1 | 2022 | 4446 | 0.070 |
Why?
|
| Survival Rate | 2 | 2018 | 12808 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 10344 | 0.070 |
Why?
|
| Fatigue | 2 | 2023 | 1544 | 0.060 |
Why?
|
| Adult | 11 | 2024 | 219994 | 0.060 |
Why?
|
| Retrospective Studies | 7 | 2023 | 80372 | 0.060 |
Why?
|
| Aged | 8 | 2024 | 169152 | 0.060 |
Why?
|
| Female | 12 | 2024 | 391270 | 0.060 |
Why?
|
| Influenza, Human | 1 | 2015 | 1528 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2024 | 54303 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2020 | 4878 | 0.050 |
Why?
|
| Radiography | 1 | 2014 | 6965 | 0.050 |
Why?
|
| Young Adult | 5 | 2024 | 58741 | 0.050 |
Why?
|
| Middle Aged | 9 | 2024 | 220352 | 0.050 |
Why?
|
| Neoplasms | 3 | 2020 | 22072 | 0.050 |
Why?
|
| Age Factors | 1 | 2018 | 18416 | 0.050 |
Why?
|
| Anorexia | 1 | 2021 | 154 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2022 | 6828 | 0.050 |
Why?
|
| Fever | 2 | 2021 | 1617 | 0.050 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2022 | 161 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 11712 | 0.050 |
Why?
|
| Male | 8 | 2024 | 359744 | 0.040 |
Why?
|
| Hepatitis | 1 | 2021 | 230 | 0.040 |
Why?
|
| DNA, Neoplasm | 1 | 2024 | 1745 | 0.040 |
Why?
|
| Death | 1 | 2023 | 678 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2021 | 642 | 0.040 |
Why?
|
| Brain | 2 | 2022 | 26951 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2022 | 36290 | 0.040 |
Why?
|
| New England | 1 | 2020 | 1050 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 556 | 0.040 |
Why?
|
| Vomiting | 1 | 2020 | 650 | 0.030 |
Why?
|
| Exanthema | 1 | 2021 | 504 | 0.030 |
Why?
|
| Central Nervous System | 1 | 2023 | 1334 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 39261 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 13262 | 0.030 |
Why?
|
| Leukoencephalitis, Acute Hemorrhagic | 1 | 2015 | 19 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2021 | 2648 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2021 | 5643 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2021 | 1613 | 0.030 |
Why?
|
| Perception | 1 | 2020 | 1195 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 9276 | 0.030 |
Why?
|
| Amnesia | 1 | 2015 | 255 | 0.030 |
Why?
|
| Colitis | 1 | 2021 | 1229 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 21025 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 3839 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2019 | 65017 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2020 | 1380 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2019 | 1375 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2022 | 8552 | 0.020 |
Why?
|
| Piperazines | 1 | 2021 | 2525 | 0.020 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 1547 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 4902 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 25942 | 0.020 |
Why?
|
| Pyridines | 1 | 2021 | 2879 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 3844 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2021 | 10182 | 0.020 |
Why?
|
| Mutation | 2 | 2024 | 29932 | 0.020 |
Why?
|
| Disease Management | 1 | 2019 | 2514 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 10827 | 0.020 |
Why?
|
| Rhinitis | 1 | 2015 | 746 | 0.020 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 2299 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 14495 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 15289 | 0.020 |
Why?
|
| Genomics | 1 | 2021 | 5794 | 0.020 |
Why?
|
| Disease Progression | 1 | 2022 | 13502 | 0.020 |
Why?
|
| Doxorubicin | 1 | 1990 | 2209 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 4319 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2024 | 58995 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2019 | 41335 | 0.010 |
Why?
|
| Adolescent | 1 | 2022 | 87810 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1990 | 641 | 0.000 |
Why?
|
| Liposomes | 1 | 1990 | 777 | 0.000 |
Why?
|
| Drug Carriers | 1 | 1990 | 709 | 0.000 |
Why?
|
Concepts
(133)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(90)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_